Savara Inc Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Savara Inc (SVRA) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $361.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-11
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $361.00K.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2.00K.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $17.00K.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $46.00K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $361.00K 10-Q · filed 2026-08-11 |
| 2025-12-31 | $2.00K 10-K · filed 2026-03-13 |
| 2024-12-31 | $17.00K 10-K · filed 2025-03-27 |
| 2023-12-31 | $46.00K 10-K · filed 2024-03-07 |
| 2022-12-31 | $7.00K 10-K · filed 2023-03-30 |
| 2021-12-31 | $21.00K 10-K · filed 2022-03-30 |
| 2020-12-31 | $8.00K 10-K · filed 2021-03-10 |
| 2020-09-30 | $8.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $15.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $23.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $42.00K 10-K · filed 2020-03-12 |
| 2019-09-30 | $57.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $80.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $107.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |